Skip to content

#政策/支付

Today 0 items
Oct 15Thu
  1. fda.gov53

    FDA Rare Disease Innovation Hub

    The FDA Rare Disease Innovation Hub released its Strategic Agenda on February 2, 2026, setting out its goals and priorities for the coming year for the rare disease community. The Hub, co-led by the directors of CBER, CDER and CDRH with the Oncology Center of Excellence and Office of Orphan Products Development, will focus on products for smaller populations and diseases with variable, poorly understood natural history. It has scheduled public meetings for October 16 and October 28, 2026.

  2. fda.gov51

    FDA Rare Disease Framework Initiative Public Meeting - 10/28/2026

    The FDA, with the Reagan-Udall Foundation for the FDA, will hold a hybrid public meeting on October 28, 2026, from 1:00 p.m. to 5:00 p.m. ET at the FDA White Oak Campus in Silver Spring, Maryland, and via Zoom. The meeting seeks input from patients, advocates, sponsors and others on the FDA's Rare Disease Framework Initiative, which aims to build a fit-for-purpose approach to rare disease drug development in small patient populations. Public remarks will inform the agency's work on the Framework, with input sought on fit-for-purpose review, regulatory predictability, external engagement and CMC considerations.

  3. fda.gov62

    FDA Launches the Rare Disease Framework Initiative to Develop a Holistic, Fit-For-Purpose Framework for Rare Disease Drug Development

    The FDA launched the Rare Disease Framework Initiative to build a fit-for-purpose framework for developing drugs and biologics for rare diseases, outlined in a new white paper dated October 14, 2026. The initiative, led by the Rare Disease Innovation Hub with the Commissioner's office, CBER and CDER, will tailor regulatory requirements to small patient populations, with only about 5% of rare conditions having an FDA-approved treatment. A public meeting on October 28 at the White Oak campus, facilitated by the Reagan-Udall Foundation, opens a feedback process that will inform new guidance, regulation revisions, training and organizational changes.

  4. fda.gov63

    Rare Disease Framework

    The FDA, with the Reagan-Udall Foundation for the FDA, will hold a hybrid public meeting on October 28, 2026, to gather input on its Rare Disease Framework Initiative, which aims to reimagine the agency's approach to rare disease drug development and review. The framework would tailor regulatory advice and decision-making to the evidence reasonably attainable for each disease, embed the patient voice at defined milestones, leverage external expertise, and apply risk-based approaches to manufacturing review and inspections. Changes could come through regulations, guidance documents and internal processes; FDA set out its aims in a white paper released October 14, 2026.

    Why it matters: FDA's rare disease development and review overhaul could change regulatory expectations for sponsors of orphan drugs.

Oct 14Wed
  1. fda.gov47

    Help More Providers Prescribe with Confidence

    FDA's Center for Drug Evaluation and Research runs Prescribe with Confidence, an educational campaign to help health care providers recognize and treat opioid use disorder and prescribe medications for opioid use disorder when appropriate. The campaign aligns with the Great American Recovery Initiative and lists SAMHSA, NIDA, CDC, HRSA, NRHA, PCSS, the Reagan-Udall Foundation and the American Academy of Family Physicians among its partners. FDA offers free downloadable materials, provider video testimonials and sample social media posts under #PrescribeWithConfidence for organizations to share.

  2. fda.gov43

    BsUFA II: Fiscal Years 2018 - 2022

    FDA is implementing BsUFA II, the Biosimilar User Fee Act programme covering fiscal years 2018 through 2022, under the Biosimilar User Fee Amendments of 2017, Title IV of the Food and Drug Administration Reauthorization Act. The prior BsUFA authority, authorized in 2012 by FDASIA, expired in September 2017, and the FD&C Act required FDA to hold public meetings and negotiate with industry on the reauthorization, including an October 20, 2016 public meeting and steering and finance committee discussions during 2016. The page lists the BsUFA II commitment letter, performance goals, hiring data and implementation plans for enhanced review transparency and communication.

Oct 12Mon
  1. fda.gov73

    Hiding in Plain Sight: 7-OH Products

    DEA issued two new Notices of Intent on October 9, 2026, based on updated HHS analysis, proposing threshold-based Schedule I control for 7-hydroxymitragynine (7-OH) and mitragynine pseudoindoxyl (MGPI). HHS recommends Schedule I when either substance, or their combined amount, exceeds 1 milligram per gram in solids or 1 milligram per milliliter in liquids, or when the mitragynine ratio to them falls below 100 to 1. DEA will reissue its Notice of Intent without changing the current scheduling approach for MGM-15 and MGM-16, which were temporarily placed in Schedule I on August 26, 2026; controls stay in effect during the 30-day notice period and until a new temporary scheduling order.

    Why it matters: DEA sets quantitative thresholds that decide which kratom-derived opioid products fall under Schedule I control.

Oct 9Fri
  1. ema.europa.eu55

    Clinical trial applications advice pilot becomes permanent

    The EMA's Accelerating Clinical Trials in the EU (ACT EU) advice pilot, which gives sponsors consolidated pre-submission feedback from Member States on clinical trial applications via CTIS, will become permanent from January 2027. The procedure is coordinated by the Heads of Medicines Agencies through its Clinical Trials Coordination Group. A final report covering roughly 30 pilot applications is due before the end of 2026, with updated guidance and templates published in January 2027.

Oct 8Thu
  1. fda.gov41

    Recently Issued Guidance Documents

    The FDA has released a set of guidance documents for industry and agency staff issued from July to September 2026. The list includes final guidances on blood collection and storage systems for blood components using the buffy coat method, formal PDUFA meetings, cancer clinical trial eligibility criteria on laboratory values, washout periods and performance status, and FAQs for cellular and gene therapy products. Draft guidances cover premarket approval electronic submission templates, potency assessment of active immunotherapy products, container closure systems for drugs, biologicals and biosimilars.

Oct 6Tue
  1. fda.gov49

    CDER Quantitative Medicine Center of Excellence (QM CoE)

    FDA's Center for Drug Evaluation and Research has established a Quantitative Medicine Center of Excellence to coordinate and standardize the use of quantitative medicine in drug development and regulatory decision-making across CDER. The center will work across three areas: Applied Regulatory Science, Enterprise Planning and Coordination, and Education and Ecosystem Development, covering knowledge management, policy development, strategic planning and stakeholder engagement. Its 2025 Progress and Priorities Report sets out recent accomplishments.

Oct 5Mon
  1. fda.gov46

    FDA Seeks Public Input to Support Ibogaine Research

    The FDA issued a request for information on approaches it is considering for designing early-phase clinical trials of ibogaine drug products, covering dose selection and escalation, care setting, safety monitoring, eligibility, stopping rules and safety oversight. Proposed trial elements include small, sequential dose-ascending groups with a starting dose not exceeding 10 mg/kg, and monitoring for cardiac and neurologic adverse events. Comments can be submitted for 45 days via Docket No. FDA-2026-N-10429, closing November 20, 2026, and may inform FDA approaches to ibogaine drug development.

Oct 3Sat
  1. fda.gov51

    Transparency Makes Modern Regulatory Science Stronger — FDA’s Transparency Roadmap

    The FDA has released a Transparency Roadmap covering FY26 milestones and FY27 priorities, aiming to maximize disclosure of its regulatory reasoning. A centerpiece is its complete response letter disclosure initiative, launched in 2025 with more than 200 letters covering applications submitted between 2020 and 2024, after a 2015 internal analysis found 85 percent of the FDA's safety and efficacy concerns went unmentioned in sponsors' public announcements of non-approvals. The agency also plans rulemaking to disclose the fact of submission of NDAs, BLAs and ANDAs, and is encouraging sponsors to make IND filings public, as about 96 percent of novel drug or biologic filings are already disclosed.

    Why it matters: FDA transparency roadmap details new CRL and application disclosure policies that affect how sponsors communicate regulatory setbacks.

Oct 1Thu
  1. fda.gov46

    FDA Adverse Event Monitoring System (AEMS) Electronic Submissions

    FDA is implementing the Adverse Event Monitoring System (AEMS), formerly FAERS, to consolidate reporting across all FDA-regulated product categories, with AI-based redaction, enhanced analytics and cross-product surveillance. From October 1, 2026, postmarketing individual case safety reports for human drugs, biologics and drug- or biologic-led combination products submitted via ESG NextGen must use E2B(R3) data standards, a six-month extension of the prior timeline; E2B(R2) remains accepted through September 30, 2026. Electronic submission of premarketing IND safety reports in E2B(R3) format became mandatory on April 1, 2026 for commercial IND sponsors using database-to-database transmission.

    Why it matters: Sets firm 2026 deadlines and data standards for electronic adverse event reporting that affect every drug and biologics company's pharmacovigilance operations.

Sep 21Mon
  1. fda.gov54

    FDA Updates Regulations to Advance Innovative Alternatives to Animal Testing

    The FDA issued a direct final rule on September 21, 2026 clarifying that non-animal methods, such as human cells, organs-on-chips and computer models, can be used where appropriate for safety testing of human drugs and biological products before trials in people. The rule replaces terms like "animal tests" with "nonclinical tests" and "nonclinical studies," as defined under FDORA 2022, and does not eliminate animal studies or change evidentiary standards. The FDA also launched a database with 25 examples of New Approach Methodologies from its review materials, and the public may comment; significant adverse comments would lead the agency to withdraw the rule and proceed via a companion proposed rule.

    Why it matters: FDA rulemaking directly changes nonclinical testing options for drug developers preparing human trials.

CBACBA Frontier Insights (CFI)Chinese Biopharmaceutical Association (CBA)www.cba-usa.org